Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...

The ROSELLA trial showed relacorilant plus nab-paclitaxel improved progression-free survival in platinum-resistant ovarian cancer patients. Relacorilant reduced disease progression risk by 30% and ...

The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line ...

Sapanisertib combined with weekly paclitaxel improved PFS in platinum-resistant ovarian cancer, reducing the risk of death by 34% compared to paclitaxel alone. The combination therapy was generally ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

The 81 patients with platinum-resistant ovarian cancer (cancer recurrence within six months of receiving a platinum-based chemotherapy) enrolled in the trial were randomized to have the choice of ...

AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...

Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...